Aquinox Pharmaceuticals, Inc. (AQXP) Stock Rating Reaffirmed by Canaccord Genuity
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity in a research report issued on Tuesday. They currently have a $22.00 price target on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 108.14% from the company’s previous close.
Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Finally, ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Aquinox Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $22.50.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.54 on Tuesday, reaching $10.57. The company had a trading volume of 85,700 shares, compared to its average volume of 86,947. Aquinox Pharmaceuticals has a 12-month low of $10.20 and a 12-month high of $19.97.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.